Carrie House, PhD

Carrie House, PhD

Carrie House, PhDSan Diego State University Research FoundationSan Diego, CA Role of Macrophages in the Development of Drug-Resistant Ovarian Cancer Stem Cells Following Chemotherapy Ovarian cancer is the deadliest gynecological cancer in the United States and is associated with a high rate of recurrence. Unfortunately, tumors that grow back stop responding to chemotherapy and become […]

Lori Brotto, PhD

Lori Brotto

Lori Brotto, PhDThe University of British Columbia2022 Maxine & Julie Eisen Pilot Study Award eSense Cancer: Adapting an online intervention for sexual health concerns to ovarian cancer Sexual health concerns are common after treatment of ovarian cancer, yet effective and accessible treatments to manage those concerns are not available. Dr. Brotto’s team has developed an […]

Priyanka Verma, PhD

Priyanka Verma

Priyanka Verma, PhDWashington University, St. Louis2022 MCM Pilot Study Award Targeting drug resistance in BRCA-mutant ovarian cancers by exploiting endogenous base damage Many ovarian cancers are caused by mutations in proteins that usually function to repair DNA damage. These cancer cells with accumulated DNA damage are targeted by PARP inhibitor therapies. Despite ovarian tumors showing […]

Hector Franco, PhD

Hector Franco

Hector Franco, PhDUniversity of North Carolina, Chapel Hill2022 Lester and Bernice Smith Pilot Study Award Identifying Drivers of Therapeutic Resistance in Ovarian Cancer at Single-Cell Resolution Ovarian cancer is one of the deadliest cancers among women worldwide. Most women respond well to the standard treatment; however, up to 75% of these patients experience a recurrence […]

Toni Antalis, PhD

Toni Antalis

Toni Antalis, PhDUniversity of Maryland, Baltimore2022 Rosser Family Pilot Study Award Emerging roles of MASP activation in ovarian cancer metastasis and acquired chemoresistance While ovarian cancer responds well to initial treatments, it frequently returns due to acquired chemotherapy resistance. Although chemotherapies aim slow or stop tumor growth, cancer cells continue to evolve between chemotherapy cycles. […]

Sneha Saxena, PhD

Sneha Saxena

Sneha Saxena, PhDMassachusetts General Hospital2022 James A. Harting Scientific Scholar Award Targeting ovarian cancer by exploiting a novel type of replication stress induced by unprocessed uracil in DNA Despite decades of work to develop new treatments, the five-year survival of patients with advanced ovarian cancer is between 10-30 percent. Hence, there is a pressing need […]

Sarah Gitto, PhD

Sarah Gitto

Sarah Gitto, PhDUniversity of Pennsylania2022 Pape Family Scientific Scholar Award Transcriptomic and proteomic analysis of tumor-specific TILs to enhance immunotherapy in ovarian cancer Immunotherapies aim to enhance the immune system’s capability of eliminating disease within the body. Often, immunotherapy for cancer targets a type of immune cell called T cells to activate their ability to […]

Z. Ping Lin, PhD


Targeting STAT3 Signaling for Immune Checkpoint Blockade to Augment PARP Inhibitor Therapy in BRCA-Mutated Ovarian Cancer  PARP inhibitors and immune checkpoint inhibitors are two promising new therapies for ovarian cancer patients who have mutations in the BRCA gene. BRCA-mutated ovarian cancer cells produce a protein called PD-L1 to avoid being recognized and killed by immune […]

Weei-Chin Lin, MD, PhD

Novel approaches to target MYC in ovarian cancer Many ovarian cancers express the cancer-causing MYC protein at unusually high levels. The activation of MYC is a hallmark of cancer initiation, progression, and resistance to therapy. Unfortunately, MYC is one of the most difficult proteins to target therapeutically. Development of an effective therapy against MYC activity […]

David George Huntsman, MD

Combining MEK inhibition with oncolytic viral therapy as a novel treatment for low grade serous ovarian carcinoma Low grade serous ovarian cancer (LGSC) is a rare form of ovarian cancer accounting for about 5% of ovarian cancer cases. While LGSC grows relatively slowly, it is stubbornly resistant to almost all therapeutics. As a result, outcomes […]